Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | FUT6 | P51993 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19768686 | 1.00 | F12 (0.41) | F12CHRNB2CHRNA4CYP2C9P2RX7 | |
| SCHEMBL19768685 | 0.86 | P2RY2 (0.42) | DAO | |
| SCHEMBL25697669 | 0.86 | P2RY2 (0.42) | DAO | |
| SCHEMBL19834965 | 0.81 | TK2 (0.45) | CHRNB2CHRNA4 | |
| SCHEMBL25697671 | 0.80 | MEN1 (0.48) | — | |
| SCHEMBL19834972 | 0.80 | TK2 (0.46) | CHRNB2CHRNA4 | |
| SCHEMBL19768688 | 0.80 | MEN1 (0.48) | — | |
| SCHEMBL19768689 | 0.79 | P2RY2 (0.40) | — | |
| SCHEMBL25697678 | 0.79 | P2RY2 (0.40) | — | |
| SCHEMBL16373946 | 0.77 | TK1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230193287-A1 | Nucleic Acid Compounds for Binding Growth Differentiation Factor 11 | SOMALOGIC OPERATING CO., INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230193287-A1 | Nucleic Acid Compounds for Binding Growth Differentiation Factor 11 | MSTN, S100A11, IGF2BP1 | F12 2041/4885CHRNB2 3872/4885CHRNA4 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.